Covington, Kentucky Clinical Trials

A listing of Covington, Kentucky clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 60 clinical trials
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

measurable disease
cancer
lymphoma
epidermal growth factor receptor
small cell lung cancer
University of Cincinnati Cancer Institute /ID# 216800
 (3.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
Tipifarnib for the Treatment of Advanced Solid Tumors Lymphoma or Histiocytic Disorders With HRAS Gene Alterations a Pediatric MATCH Treatment Trial

This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have HRAS genetic alterations. Tipifarnib may block the growth of cancer cells that have specific genetic changes in …

refractory non-hodgkin lymphoma
cancer treatment
stem cell infusion
corticosteroids
hras gene
Cincinnati Children's Hospital Medical Center
 (6.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +82 other locations
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas

Subjects with Neurofibromatosis Type 2 (NF2) and progressive vestibular schwannoma (VS) will be treated with crizotinib administered orally. Crizotinib will be taken continuously until disease progression or unacceptable toxicity, in continuous treatment cycles of 28 days each, for a maximum of 12 cycles.

nf2 gene
schwartz
measurable disease
neurofibroma
crizotinib
Cincinnati Children's Hospital Medical Center (Site 800)
 (6.0 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +16 other locations
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields

The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.

triamcinolone
clindamycin
malignant glioma
ttfields
tumor treating fields therapy
University of Cincinnati Medical Center
 (3.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +6 other locations
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection

Purpose of Study The purpose of this study to evaluate, the effectiveness of convalescent plasma in combatting the symptoms and effects of the coronavirus disease, COVID-19. Beyond supportive care, there are no proven treatment options for COVID-19.

oximetry
acute respiratory syndrome (sars)
chest x-ray
x-rays
SARS
Good Samaritan Hospital
 (5.1 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort

The Parkinson Progression Marker Initiative 2.0 (PPMI 2.0) is a longitudinal, observational, multi-center natural history study to assess progression of clinical features, digital outcomes, and imaging, biologic and genetic markers of Parkinson's disease (PD) progression in study participants with manifest PD, prodromal PD, and healthy controls The overall goal of …

methyldopa
tremor
muscle rigidity
modafinil
alpha-synuclein
University of Cincinnati/Cincinnati Children's Hospital
 (3.9 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +45 other locations
A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants

The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.

Seven Hills Clinical Research Group
 (8.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

eliglustat
gaucher disease
deficiency
imiglucerase
Investigational Site Number 840026
 (2.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840041
 (2.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations
Pompe Disease Registry

The Pompe Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Pompe disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The objectives …

gaa gene
glycogen storage disease type ii
myozyme
deficiency
replacement therapy
Investigational Site Number 840041
 (2.3 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +190 other locations